Suppr超能文献

曲格列汀(MSI-1436)抑制 PTP1B 可导致饮食诱导肥胖小鼠的特异性脂肪体重减轻。

Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice.

机构信息

Department of Preclinical Research, Genaera Corporation, Plymouth Meeting, Pennsylvania, USA.

出版信息

Obesity (Silver Spring). 2010 Aug;18(8):1516-23. doi: 10.1038/oby.2009.444. Epub 2010 Jan 14.

Abstract

Trodusquemine (MSI-1436) causes rapid and reversible weight loss in genetic models of obesity. To better predict the potential effects of trodusquemine in the clinic, we investigated the effects of trodusquemine treatment in a murine model of diet-induced obesity (DIO). Trodusquemine suppressed appetite, reduced body weight (BW) in a fat-specific manner, and improved plasma insulin and leptin levels in mice. Screening assays revealed that trodusquemine selectively inhibited protein-tyrosine phosphatase 1B (PTP1B), a key enzyme regulating insulin and leptin signaling. Trodusquemine significantly enhanced insulin-stimulated tyrosine phosphorylation of insulin receptor (IR) beta and STAT3, direct targets of PTP1B, in HepG2 cells in vitro and/or hypothalamic tissue in vivo. These data establish trodusquemine as an effective central and peripheral PTP1B inhibitor with the potential to elicit noncachectic fat-specific weight loss and improve insulin and leptin levels.

摘要

曲朵司琼(MSI-1436)可在肥胖的遗传模型中引起快速和可逆的体重减轻。为了更好地预测曲朵司琼在临床上的潜在影响,我们在饮食诱导肥胖(DIO)的小鼠模型中研究了曲朵司琼治疗的效果。曲朵司琼抑制食欲,以脂肪特异性的方式降低体重(BW),并改善小鼠的血浆胰岛素和瘦素水平。筛选试验表明,曲朵司琼选择性抑制蛋白酪氨酸磷酸酶 1B(PTP1B),这是调节胰岛素和瘦素信号的关键酶。曲朵司琼在体外 HepG2 细胞和/或体内下丘脑组织中显著增强了胰岛素刺激的胰岛素受体(IR)β和 STAT3 的酪氨酸磷酸化,这是 PTP1B 的直接靶标。这些数据表明曲朵司琼是一种有效的中枢和外周 PTP1B 抑制剂,具有引起非肥胖特异性脂肪减轻和改善胰岛素和瘦素水平的潜力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验